Focused Disease Areas for a Stronger Business Model [Video]

A Novartis focused disease areas strategy with supporting commercial strength was outlined for investors at 2024 J.P. Morgan Healthcare Conference.

A strategy focused on core therapeutic areas where we have strong R&D, brands and commercial experience enables us to deliver high-value medicines that alleviate society’s greatest disease burdens. Our CEO, Vas Narasimhan provides an overview of these areas (cardiovascular, renal & metabolic, oncology, immunology and neuroscience) and the business foundations to support.

**This video uses audio from the webcasted event.**
J.P. Morgan Healthcare Conference
Event Date: January 08, 2024
Full webcast here: https://go.novartis.social/49012mq
Full presentation here: https://go.novartis.social/42lZfpC
Novartis JPM HC 2024 Coverage: https://go.novartis.social/3SAAJy0
Investor Relations: https://go.novartis.social/3SBMpjR
Investor Events: https://go.novartis.social/4813eJr
Novartis Strategy: https://go.novartis.social/3HEGx3d

Disclaimer: J.P. Morgan Healthcare Conference live event contains forward-looking statements. Such forward-looking statements are subject to significant known and unknown risks and uncertainties. Visit our website for more information: https://go.novartis.social/49dXdKx

The J.P. Morgan Healthcare conference live event also contains non-IFRS measures. An explanation of non-IFRS measures can be found on our website https://go.novartis.social/47UDpLa.

Learn more: https://go.novartis.social/3SAAJy0